Tumor microenvironment
The tumor microenvironment (TME) refers to the complex, dynamic ecosystem surrounding and infiltrating a malignant tumor, comprising not only cancer cells but also a heterogeneous mixture of stromal cells, immune cells, extracellular matrix components, blood vessels, and soluble signaling molecules.
The tumor microenvironment (TME) refers to the complex, dynamic ecosystem surrounding and infiltrating a malignant tumor, comprising not only cancer cells but also a heterogeneous mixture of stromal cells, immune cells, extracellular matrix components, blood vessels, and soluble signaling molecules. Far from being a passive bystander, the TME actively participates in regulating tumor initiation, progression, immune evasion, metastasis, and therapeutic resistance. Key cellular constituents include tumor-associated macrophages (TAMs), cytotoxic T cells, regulatory T cells, dendritic cells, natural killer cell, B cells, cancer-associated fibroblasts, myeloid-derived suppressor cells (MDSCs), and neutrophils, all of which engage in intricate bidirectional crosstalk with neoplastic cells through cytokines, chemokines, metabolites, and exosomes. The physical and chemical characteristics of the TME — including hypoxia, acidosis, elevated reactive oxygen species (ROS), and immunosuppressive metabolite gradients — collectively shape a milieu that frequently supports tumor survival and shields cancer cells from immune surveillance.
A defining hallmark of many TMEs is their immunosuppressive character, which drives resistance to both conventional therapies and modern immunotherapy. This immunosuppression is orchestrated through multiple overlapping mechanisms: the polarization of macrophages toward an M2-like, pro-tumorigenic phenotype; the accumulation of regulatory T cells and MDSCs; the co-expression of immune checkpoint molecules such as Programmed cell death 1 (PD-1), CD274 molecule, LAG-3, TIGIT, VISTA, and B7-H3 (CD276); and the secretion of immunosuppressive cytokines such as transforming growth factor-beta (TGF-β) and IL-10. Understanding and therapeutically reprogramming the TME has emerged as one of the central challenges and opportunities in contemporary oncology, driving research across virtually every cancer type and treatment modality.
Where the papers sit
10 papers from the last 6 months study tumor microenvironment directly · updated from PubMed 15 Nov 2026
Study type 0 clinical trials · 3 human data · 5 preclinical · 2 unclassified
Themes 3 themes
-
Molecular Drivers of Therapy Resistance
Therapy resistance is being mapped through chromatin architecture, ubiquitination, metabolism, and innate immune sensing across several cancers. Single-cell and multi-omic analyses seek cell-state signatures for LUAD evolution, neuroendocrine prostate cancer, and KRAS-mutant lung adenocarcinoma. Galactose reprogramming and cGAS-STING activation are being proposed as routes to restore anti-PD-1 sensitivity, while the gene signatures remain largely hypothesis-generating. The shared direction is toward mechanism-based biomarkers and combination treatments, not a single established intervention.
4 papers · 40%
-
Preclinical Microenvironment Remodeling
Stromal and immune remodeling is being paired with localized or nanomedicine-based treatment to make solid tumors more responsive. Extracellular-vesicle photoimmunotherapy and cuproptosis-oriented materials target the extracellular matrix and immune suppression in pancreatic ductal adenocarcinoma. HIFU and inhalable nitric oxide add physical or gas-based ways to alter the local niche and stimulate antitumor immunity. The evidence remains preclinical, and the relative contributions of stromal disruption, direct tumor killing, and immune activation are unresolved.
3 papers · 30%
-
Cancer Immune Modulation
Immune activity in tumors is being treated as a metabolic and behavioral system rather than a fixed property of cancer cells. Tumor-derived antioxidants can deprive T cells of reactive oxygen species, while PI3Kγ inhibition and membrane-active peptides aim to reprogram suppressive macrophage-rich niches. Physical activity is linked to immune-cell infiltration in non-metastatic colon cancer, but the association does not establish treatment benefit. The field is moving toward combining host-level interventions with microenvironment-directed immunotherapy.
3 papers · 30%
Papers
The 10 papers from the last 6 months that study tumor microenvironment directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Molecular Drivers of Therapy Resistance (4)
- "Yong" syndrome-cGAS-STING axis: a TCM syndrome-based hypothesis for overcoming primary anti-PD-1 resistance in gastric cancer. Journal for immunotherapy of cancer · 4 Aug 2026 PMID 42552062
- Targeting galactose metabolic reprogramming overcomes immunotherapy resistance in KRAS-mutant lung adenocarcinoma: Integrative multi-omics and machine learning approaches. Translational oncology · 6 Jul 2026 PMID 42407377
- Ubiquitination-anchored signature defines neuroendocrine prostate cancer: hub genes and single-cell ecosystem insights from integrated bioinformatics analysis of public transcriptomic datasets. The aging male : the official journal of the International Society for the Study of the Aging Male · 6 Jun 2026 PMID 42249833
- 3D chromatin architecture-related genes orchestrate LUAD evolution and therapy resistance: insights from integrative machine learning and spatial single-cell mapping. Functional & integrative genomics · 4 Jun 2026 PMID 42240917
Preclinical Microenvironment Remodeling (3)
- An Inhalable Hybrid Nitric Oxide Nanogenerator for Lung Adenocarcinoma Treatment via Bioorthogonal-Activated Gas-Immunotherapy. Journal of the American Chemical Society · 9 Sept 2026 PMID 42714559
- Development of a mobile high-intensity focused ultrasound platform for preclinical tumor microenvironment modulation in a pancreatic ductal adenocarcinoma mouse model. International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 18 Aug 2026 PMID 42609051
- Targeted extracellular vesicle-photoimmunotherapy remodels stromal-immune microenvironment to boost chemo-immunotherapy in preclinical models. Cell reports. Medicine · 3 Jun 2026 PMID 42235518
Cancer Immune Modulation (3)
- Association of objectively assessed physical activity with immune cell infiltration of the tumor microenvironment in non-metastatic colon cancer. International journal of colorectal disease · 10 Sept 2026 PMID 42720727
- Tumor-derived antioxidants suppress immunity by depriving T cells of reactive oxygen species. Science (New York, N.Y.) · 3 Sept 2026 PMID 42691162
- pH-Responsive liposomes co-delivering a membrane-active peptide and the PI3Kγ inhibitor to reconstruct the tumor microenvironment for enhanced antitumor immunotherapy. Biomaterials science · 17 Aug 2026 PMID 42605855
By study type
Human data, design not indexed (3)
- Association of objectively assessed physical activity with immune cell infiltration of the tumor microenvironment in non-metastatic colon cancer. International journal of colorectal disease · 10 Sept 2026 PMID 42720727
- "Yong" syndrome-cGAS-STING axis: a TCM syndrome-based hypothesis for overcoming primary anti-PD-1 resistance in gastric cancer. Journal for immunotherapy of cancer · 4 Aug 2026 PMID 42552062
- 3D chromatin architecture-related genes orchestrate LUAD evolution and therapy resistance: insights from integrative machine learning and spatial single-cell mapping. Functional & integrative genomics · 4 Jun 2026 PMID 42240917
Preclinical: animal, cell and lab studies (5)
- An Inhalable Hybrid Nitric Oxide Nanogenerator for Lung Adenocarcinoma Treatment via Bioorthogonal-Activated Gas-Immunotherapy. Journal of the American Chemical Society · 9 Sept 2026 PMID 42714559
- Tumor-derived antioxidants suppress immunity by depriving T cells of reactive oxygen species. Science (New York, N.Y.) · 3 Sept 2026 PMID 42691162
- Development of a mobile high-intensity focused ultrasound platform for preclinical tumor microenvironment modulation in a pancreatic ductal adenocarcinoma mouse model. International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 18 Aug 2026 PMID 42609051
- pH-Responsive liposomes co-delivering a membrane-active peptide and the PI3Kγ inhibitor to reconstruct the tumor microenvironment for enhanced antitumor immunotherapy. Biomaterials science · 17 Aug 2026 PMID 42605855
- Targeted extracellular vesicle-photoimmunotherapy remodels stromal-immune microenvironment to boost chemo-immunotherapy in preclinical models. Cell reports. Medicine · 3 Jun 2026 PMID 42235518
Unclassified: not yet indexed with MeSH (2)
- Targeting galactose metabolic reprogramming overcomes immunotherapy resistance in KRAS-mutant lung adenocarcinoma: Integrative multi-omics and machine learning approaches. Translational oncology · 6 Jul 2026 PMID 42407377
- Ubiquitination-anchored signature defines neuroendocrine prostate cancer: hub genes and single-cell ecosystem insights from integrated bioinformatics analysis of public transcriptomic datasets. The aging male : the official journal of the International Society for the Study of the Aging Male · 6 Jun 2026 PMID 42249833
Written from 10 PubMed abstracts, each one listed by PMID above. Published: 2026-06-14. Last written: 2026-09-12 by GPT. Drafted by language models from published abstracts; not medical advice.